Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO in severe and very severe aplastic anemia
NCT02857530Phase 2
Key facts
- Status
- Unknown
- Start
- Aug 2016
- Primary completion
- Jul 2019
- Countries
- 1
- Sponsor
- Tianjin Medical University General Hospital
- Conditions
- aplastic anemia
01
Overview
Phase 2, randomised, double-blind trial of recombinant human thrombopoietin in aplastic anemia, sponsored by Tianjin Medical University General Hospital. Status: unknown.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Patients with severe or very severe aplastic anemia, excluding those with Fanconi anemia, large PNH clones, or significant organ dysfunction.
04
Registry description
Efficacy and Safety of Recombinant human thrombopoietin in patients with severe aplastic anemia and very severe aplastic anemia, a randomized, double-blind, placebo-controlled, II phase, multi-center clinical research.
Beyond the preview
Go deeper on NCT02857530.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02857530.